Li Ling, Zhu Tao, Gao Yuan-Feng, Zheng Wei, Wang Chen-Jing, Xiao Ling, Huang Ma-Sha, Yin Ji-Ye, Zhou Hong-Hao, Liu Zhao-Qian
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China.
Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha 410078, China.
Int J Mol Sci. 2016 May 31;17(6):839. doi: 10.3390/ijms17060839.
Lung cancer is the leading cause of cancer death worldwide due to its high incidence and mortality. As the most common lung cancer, non-small cell lung cancer (NSCLC) is a terrible threat to human health. Despite improvements in diagnosis and combined treatments including surgical resection, radiotherapy and chemotherapy, the overall survival for NSCLC patients still remains poor. DNA damage is considered to be the primary cause of lung cancer development and is normally recognized and repaired by the intrinsic DNA damage response machinery. The role of DNA repair pathways in radio(chemo)therapy-resistant cancers has become an area of significant interest in the clinical setting. Meanwhile, some studies have proved that genetic and epigenetic factors can alter the DNA damage response and repair, which results in changes of the radiation and chemotherapy curative effect in NSCLC. In this review, we focus on the effect of genetic polymorphisms and epigenetic factors such as miRNA regulation and lncRNA regulation participating in DNA damage repair in response to radio(chemo)therapy in NSCLC. These may provide novel information on the radio(chemo)therapy of NSCLC based on the individual DNA damage response.
肺癌因其高发病率和死亡率,成为全球癌症死亡的主要原因。作为最常见的肺癌类型,非小细胞肺癌(NSCLC)对人类健康构成严重威胁。尽管在诊断以及包括手术切除、放疗和化疗在内的联合治疗方面有所改善,但NSCLC患者的总体生存率仍然很低。DNA损伤被认为是肺癌发生的主要原因,通常由内在的DNA损伤反应机制识别和修复。DNA修复途径在耐放(化)疗癌症中的作用已成为临床环境中一个备受关注的领域。同时,一些研究证明,遗传和表观遗传因素可改变DNA损伤反应和修复,从而导致NSCLC放疗和化疗疗效的变化。在本综述中,我们重点关注基因多态性和表观遗传因素(如miRNA调控和lncRNA调控)对NSCLC放(化)疗后DNA损伤修复的影响。这些可能为基于个体DNA损伤反应的NSCLC放(化)疗提供新信息。